Clinical trials: Healthy Males
Anemia, Sickle Cell
A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects
This study will provide information regarding the metabolic pathway of GBT440, the need for evaluation of potential drug-drug interactions, and the need for studies in special populations.
- Trial name
- NCT02497924
- Testing
- GBT440
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Global Blood Therapeutics
Healthy
This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men
The primary objective of this trial is to investigate the safety and tolerability of BI 1265162 in healthy male subjects following inhalative administration of single rising doses.
- Trial name
- NCT03349723
- Testing
- BI 1265162
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Gout, Coronary Artery Disease
Uric Acid Study in Healthy Male Volunteers
This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.
- Trial name
- NCT00738842
- Testing
- AZD6140
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
Safety, Tolerability, and Dose Response of VNA-318 in Healthy Males
This is a phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (SAD) and multiple ascending doses (MAD) of VNA-318 in…
- Trial name
- NCT06721091
- Testing
- VNA-318
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- VANDRIA
Psoriasis Vulgaris
Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.
This trial will investigate the safety, tolerability and pharmacokinetic (PK) data of LEO 32731 (and major human metabolite LEO 40815) in healthy male Japanese subjects.
- Trial name
- NCT03231124
- Testing
- LEO 32731
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Bioequivalence
Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fed Conditions
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x4, replicated, two treatments, four periods, two sequences controlled clinical study
- Trial name
- ACL25-PC007 (NCT07698288)
- Testing
- Tamsulosin 0.4 mg ER tablet
- Where
- Mexico
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- ADIUM
Liver Cirrhosis
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants
This study aim to assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants.
- Trial name
- NCT06715670
- Testing
- Zibotentan
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose
This is an open-label, Phase I study. Study treatments will entail a four-way crossover among three single, ascending, subcutaneous doses and one intravenous dose of MNTX in six healthy normal male volunteers.
- Trial name
- NCT01367496
- Testing
- SC Methylnaltrexone (MNTX), IV Methylnaltrexone (MNTX)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Healthy
Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers
The objective was to investigate whether there was a drug-drug interaction between BI 10773 and sitagliptin when co-administered as multiple oral doses.
- Trial name
- NCT02172196
- Testing
- BI 10773, Sitagliptin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Invasive Aspergillosis
Single Ascending Oral Dose Study of F901318
Double blind, placebo controlled, ascending single oral dose, sequential group study. Forty subjects will complete the study in 5 cohorts (Groups A to E), each group consisting of 8 subjects.
- Trial name
- NCT02394483
- Testing
- F901318 safety, F901318 tolerability, F901318 pharmacokinetics
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Healthy
Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers
The study was aimed to evaluate the pharmacological effect of different α-antagonists on phenylephrine induced pupil size in healthy male volunteers as pharmacological basis for Intraoperative floppy iris syndrome (IFIS)
- Trial name
- NCT02266537
- Testing
- Tamsulosin, Alfuzosin, Doxazosin
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood
The main objective of this trial is to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of BI 1291583 at steady state.
- Trial name
- NCT06917872
- Testing
- BI 1291583, erythromycin
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Erectile Dysfunction
The Effects of a Nitrate Supplementation on Erectile Function
Twenty (20) individuals to be recruited from Ballantyne Medical Associates in Charlotte, NC, without any significant chronic medical history. These patients are general patients for primary care that meet inclusion criteria.
- Trial name
- NCT06213077
- Testing
- Nitric Oxide, Tadalafil
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RHA Investments Ltd
Healthy
Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.
The objective of the current study is to investigate safety, tolerability, and pharmacokinetics of treatment with BI 661051 rising single doses administered as oral drinking solution (powder in bottle) in healthy male subjects.
- Trial name
- NCT01343719
- Testing
- BI 661051
- Where
- Germany
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Renal Cell Carcinoma, Cancer
TRACERx Renal CAPTURE Sub-study
TRACERx Renal: This is a translational study, which, aims to develop prognostic and predictive biomarkers for patients with renal cell carcinoma (RCC).
- Conditions
- Renal Cell Carcinoma, Cancer, Healthy Volunteers
- Trial name
- TRACERxRenal (NCT03226886)
- Where
- 4 sites in United Kingdom
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Healthy
Investigation of Single Rising Doses of BI 685509
To investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising oral doses of BI 685509
- Trial name
- NCT02694354
- Testing
- BI 685509
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Males
Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects
Part 1 : A randomized, open Label, multiple doses, cross-over, phase I trial to investigate the pharmacokinetics of Pelubiprofen IR (Pelubiprofen 30mg) TID and Pelubiprofen SR (Pelubiprofen 45 mg) BID in healthy male volunteers…
- Trial name
- NCT01870102
- Testing
- Pelubiprofen IR (Pelubiprofen 30mg) TID, Pelubiprofen SR (Pelubiprofen 45 mg) BID
- Volunteers
- healthy volunteers welcome
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Healthy
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
The purpose of this study is to describe the single dose pharmacokinetics of total radioactivity in plasma and whole blood following PO administration of [14C] TR-701 in healthy adult male subjects.
- Trial name
- NCT01442831
- Testing
- Human ADME
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Healthy
A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection
This trial is a randomized, double-blind, three-arm, parallel-group, pharmacokinetic study. The purpose of this study is to demonstrate pharmacokinetic (PK) similarity and to compare safety, immunogenicity and pharmacodynamics…
- Trial name
- NCT06095427
- Testing
- LY06006 (Denosumab Biosimilar), US-Prolia (Denosumab), EU-Prolia
- Where
- 2 sites in Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Rheumatoid Arthritis
A Multiple Dose of HL237 in Healthy Male Subject
HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic structure of biguanide in metformin, an existing diabetes drug. The immune modulating activity of HL237 was demonstrated in animal model.
- Trial name
- NCT03896594
- Testing
- HL237
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.